ArticleScientific reports2026
Abdominal massage improves intestinal barrier function via the TLR4/MyD88/NF-κB signaling pathway in obesity-associated T2DM rats.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Abdominal massage (AM), a traditional Chinese medicine treatment, is gradually being recognized in clinical practice for its ability to improve the symptoms of obesity and type 2 diabetes mellitus (T2DM) in clinical practice. This study aimed to investigate the effect of AM on an obesity-associated T2DM model induced by a high-fat diet (HFD) combined with a small dose of streptozotocin (STZ). Thirty male Sprague‒Dawley rats were randomly divided into three groups: control group (CON), the obesity-associated T2DM group (MOD), and AM group. After 4 weeks of HFD feeding and STZ injection, the rats received AM for 4 weeks. AM significantly improved glucose intolerance, obesity, and colonic inflammation and reduced fasting blood glucose and glycated serum protein levels. In addition, AM significantly ameliorated glucolipid metabolism abnormalities in obesity-associated T2DM rats, as evidenced by improved glucose tolerance and favorable alterations in lipid profiles. AM also attenuated both systemic and intestinal inflammation, accompanied by a marked reduction in circulating pro-inflammatory cytokines. In summary, our results suggest that AM exerts protective effects against obesity-associated T2DM by improving glucolipid metabolism, attenuating systemic and intestinal inflammation, and restoring intestinal barrier integrity via suppression of the TLR4/MyD88/NF-κB signaling pathway. Although long-term evaluations and multi-omics analyses are warranted to fully elucidate the underlying mechanisms, these results provide a solid theoretical basis for exploring AM as a potential barrier-protecting therapeutic strategy for obesity-related metabolic diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.